Journal of Infectious Diseases & Preventive Medicine
Open Access

Panagiotis Gargalianos-Kakolyris

Publications

• Research Article
  In Vivo Effects of Tenofovir-DF/Emtricitabine and Abacavir/Lamivudine with Atazanavir-R on Platelet Activating Factor Metabolism in HIV Naive Patients
  Author(s): Vasiliki D Papakonstantinou, Maria Chini, Nikos Mangafas, George Stamatakis, Athina Lioni, Nickolaos Tsogas, Elizabeth Fragopoulou, Panagiotis Gargalianos-Kakolyris, Constantinos A Demopoulos, Smaragdi Antonopoulou and Marios C Lazanas Vasiliki D Papakonstantinou, Maria Chini, Nikos Mangafas, George Stamatakis, Athina Lioni, Nickolaos Tsogas, Elizabeth Fragopoulou, Panagiotis Gargalianos-Kakolyris, Constantinos A Demopoulos, Smaragdi Antonopoulou and Marios C Lazanas
  
  Antiretroviral therapy (ΑRT) has successfully decreased AIDS morbidity and mortality and increased the lifespan of HIV patients to several decades. However, numerous factors contribute with unknown mechanisms to chronic immune activation and inflammation leading to severe “non-AIDS morbidities’’. Platelet Activating Factor (PAF) is a potent lipid inflammatory mediator with important role in the ‘’non-AIDS morbidities’’. The purpose of this study was to investigate whether tenofovir-DF/emtricitabine and abacavir/lamivudine with atazanavir boosted ritonavir (ART_A and ART_B, respectively) affect in vitro PAF activity and in vivo PAF levels and metabolism. In this intent, the two ART regimens were examined in vitro against platelet aggregation induced by PAF. In addition, PAF levels and PAF metabolic enzymes were determined in HIV-1 infecte.. View More»
  DOI: 10.4172/2329-8731.1000148

  Abstract PDF

Relevant Topics